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Abstract
Small molecules can provide valuable tools to investigate virus biology. We developed a chemical screening approach to identify small
molecule inhibitors of poorly understood, pre-early gene expression steps in herpes simplex virus infection, using green fluorescent protein fused
to an early protein. Our assay identified ouabain, a cardiac glycoside. Ouabain reversibly decreased viral yield by 100-fold without affecting
cellular metabolic activity in an overnight assay. The antiviral potencies of other cardiac glycosides correlated with their potencies against the
known target of these compounds, the cellular sodium potassium ATPase. Ouabain had a reduced effect if added 8 h post-infection. It did not
inhibit viral attachment or entry, but did reduce the expression of viral immediate–early and early genes by at least 5-fold. Collectively, these
results implicate a cellular target that was hitherto not considered important for a stage of HSV replication prior to viral gene expression.
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Immediate–early gene expressionIntroduction
Perturbation of biological systems with small molecule
inhibitors has shed much light on the function of those systems
in their uninhibited states. This is especially true for the
replication of viruses, where pharmacological research has
yielded greater understanding of the function of viral gene
products and viral interactions with the host cell, in addition to
clinically useful antiviral drugs.
Herpes simplex virus (HSV) is a clinically significant human
pathogen (reviewed in Roizman et al., 2007). The process of
HSV infection begins with attachment to a cellular receptor,
followed by entry into the cytoplasm via one of a number of host
cell-type-dependent pathways (reviewed in Spear, 2004),
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doi:10.1016/j.virol.2007.05.001cellular microtubule network (Sodeik et al., 1997), and
uncoating at the nuclear pore to insert the viral DNA and
trans-activators into the nucleus (Batterson et al., 1983).
Immediate–early and early rounds of gene expression occur,
permitting replication of the viral genome and maximal
expression of late gene products (Honess and Roizman, 1974).
Progeny virions are then assembled and egress from the host cell.
The stage of HSVDNA replication is relatively well understood,
thanks in part to a large number of known pharmacological
interventions which target this event (reviewed in Coen and
Schaffer, 2003). Comparatively less is known about other stages
in HSV infection, especially events prior to DNA replication.
More could be learned about these earlier events with the
identification of small molecule inhibitors that target them.
Towards this end, we designed a cell-based screening
approach using a virus that expresses a reporter with early
kinetics. We previously reported the construction and char-
acterization of a recombinant HSV-1 ICP8-GFP, which ex-
presses the green fluorescent protein (GFP) fused to the viral
single stranded DNA binding protein, ICP8 (Taylor et al.,
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DNA replication, and its expression indicates that the prior steps
of viral infection have already occurred successfully. We
hypothesized that this virus could be used as a reporter in a
screen to identify compounds that inhibit viral replication at a
stage prior to expression of this early protein. Our screen and
subsequent analysis identified ouabain, a well characterized
inhibitor of the cellular sodium–potassium ATPase (reviewed in
Xie and Cai, 2003), as an inhibitor of HSV replication after
entry and before immediate–early gene expression.
Results
Design and execution of a chemical screening approach
We designed a screen using a high content screening
microscope at the Harvard Institute for Cell and Chemical
Biology (ICCB). We used this assay to examine the ICCB's
known bioactive compounds library, a selection of 480
compounds with previously described biological activities.
Vero cells were plated in black, clear-bottomed 384-well plates
and incubated overnight at 37 °C, yielding confluent monolayers
of cells. Compounds were then robotically added to individual
wells in duplicate at room temperature prior to infection. ICP8-
GFP virus was added to the drug-containing media at a
multiplicity of infection (MOI) of 20, and infection was allowed
to proceed at 37 °C for 18 h. At the end of this incubation, cells
were fixed with paraformaldehyde and treated with Hoechst
33258 to stain nuclear DNA. The screening microscope was
used to record images of Hoechst and GFP fluorescence and
amounts of fluorescence were quantified using image analysis
software. Compounds that reduced the amount of GFP
fluorescence by at least one standard deviation relative to the
mean GFP signal for all compounds screened were scored as
potential hits. From the 480 compound library, 17 compounds
met this criterion. The images of the infected cells treated with
these potential hits were then examined for signal from the
Hoechst stain as a preliminary assessment of cytotoxicity. This
eliminated twelve compounds that reduced the amount of
Hoechst signal by at least one standard deviation relative to the
mean DNA signal for all compounds screened. The remaining 5
compounds, approximately 1% of compounds screened, were
ordered for secondary testing. Of these five, four compounds
either caused visually apparent toxicity or did not cause an
obvious reduction in GFP signal. The fifth compound, ouabain,
caused an obvious reduction in the level of GFP expressed by
infected cells that was visually apparent without software
quantification (Fig. 1, compare panels B and D) and did not
cause toxicity as qualitatively measured by examining the cells
under light microscopy and reduction of signal in the Hoechst
images (Fig. 1, compare panels A and C). We selected ouabain
for further study.
Dose response of ouabain inhibition of GFP fluorescence
We conducted infections in the presence of a range of
concentrations of ouabain to quantify the potency and efficacy ofouabain's inhibition of GFP fluorescence resulting from
infection with the ICP8-GFP virus (Fig. 2). The concentration
of ouabain that reduced ICP8-GFP signal by 50% in this assay
was between 14 and 140 nM. Treatment with≥140 nM ouabain
reduced nuclear GFP fluorescence produced by infected cells by
five-fold, down to a level which corresponded to the amount of
autofluorescent signal observed from untreated, uninfected cells.
Anti-HSV activity of ouabain
Ouabain was assessed for effects on viral replication using
wild-type HSV-1 strain KOS. Concentrations of ouabain
≥100 nM fully inhibited the formation of HSV-1 plaques on
a monolayer of Vero cells after 72 h. A small number of rounded
but still adherent cells, and dead floating cells, were visible in
treated, but not untreated, cells after this length of exposure, and
this effect was similar in the presence or absence of virus. As an
alternative to the plaque assay, a single cycle growth experiment
was performed to determine whether ouabain reduced viral
yield. In this assay, the concentration of drug that reduced yield
by 90% (IC90) was 40 nM, and concentrations of 100 nM or
higher consistently reduced viral yield by 100- to 10,000-fold
(Fig. 3).
A cell viability experiment was conducted to assess
whether the observed reductions in GFP expression and viral
yield during overnight treatments were caused by cytotoxi-
city, such as we had observed during the longer duration
treatment necessary for plaque formation. Confluent Vero
cells were treated with a range of concentrations of ouabain
for 24 h, and cellular metabolic activity was measured by
cleavage of a tetrazolium salt, WST-1 (Fig. 4). No dose-
dependent decrease in metabolic activity compared to
untreated cells was observed. This indicated that the antiviral
effects of ouabain in the yield assay were not associated with
cytotoxicity.
Antiviral effect of other sodium–potassium ATPase inhibitors
Ouabain is a well-characterized inhibitor of the cellular
sodium potassium ATPase (reviewed in Xie and Cai, 2003),
which is a clinically relevant drug target. As a result, detailed
structure–activity relationship data on ouabain and a variety of
other cardiac glycosides have been previously reported (Pullen
et al., 2004). A selection of inhibitors of the sodium potassium
pump was tested for effects on viral yield (Table 1). All
compounds tested reduced viral yield by 100-fold at sufficient
dosage. The antiviral potency of all of the plant-derived
inhibitors correlated with their reported potencies against the
pump (Pullen et al., 2004), though bufalin, an inhibitor derived
from toad venom, was slightly more potent against viral yield
than ouabain despite being slightly less potent against the
sodium potassium pump.
Kinetics of the anti-viral effect of ouabain
Next, we performed an experiment to determine if the
antiviral effect of ouabain was reversible. Cells that were treated
Fig. 1. Representative fluorescence images of the effect of ouabain on ICP8-GFP. The left column shows signal from the Hoechst 33258 DNA stain and the right
column displays the same field in the GFP channel. The top two rows (panels A–D) show signal for Vero cells infected with ICP8-GFP at an MOI of 10 for 18 h. Cells
in the top row (panels A and B) were mock treated, while cells in the middle row (panels C and D) were treated with 14 μM ouabain. The bottom row (panels E and F)
shows signal from mock-infected cells treated with 14 mM ouabain.
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of drug produced similar levels of virus (2.2×109 PFU/ml) to
cells that were not treated with any drug (3.6×109 PFU/ml).Fig. 2. Dose–response curve for effect of ouabain on GFP fluorescence. Images
were analyzed with Metamorph image analysis software to quantify levels of
GFP fluorescence detected after infection with ICP8-GFP virus at an MOI of 20
for 18 h in the presence of a range of concentrations of ouabain.Thus, ouabain did not cause irreversible damage to cells during
an overnight treatment. To determine whether ouabain had an
irreversible effect when present during viral replication, Vero
cells were infected with wild-type HSV at an MOI of 10 in theFig. 3. Effect of ouabain doses on viral yield. Cells were treated or mock treated
with a range of concentrations of ouabain and simultaneously infected with
wild-type HSV-1 at an MOI of 10. Viral yield was determined by titration at 24 h
post-infection.
Fig. 4. Lack of cytotoxicity of ouabain. Vero cells were treated with a range of
concentrations of ouabain and cell metabolism was measured with a WST-1
assay. The number of metabolically active cells remaining in each well at the
time of measurement was determined by comparison to a standard curve and
compared to a mock-treated control.
Fig. 5. Reversibility of ouabain treatment. Cells were treated with 100 nM
ouabain and infected with wild-type HSV-1 at an MOI of 10. At the indicated
times post-infection, the drug containing medium was removed and infection
was allowed to proceed in drug-free media. Viral yield was determined by
titration at 24 h post-infection.
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proceed. At a series of time points post-infection, the medium
was removed and replaced with drug-free media. At 24 h post-
infection, all samples were harvested and titrated to determine
viral yield (Fig. 5). No decrease in viral yield was observed
when drug was removed up to 8 h post-infection.
We then performed an experiment in which Vero cells were
infected with wt HSV-1 at an MOI of 10, and 100 nM ouabain
was added at a series of times post-infection. Output virus was
harvested at 24 h post-infection and titrated to determine viral
yield (Fig. 6). The results revealed a clear time-dependent trend,
with increased viral yield as ouabain was added later in
infection. Viral yield was reduced by 1000-fold when drug was
added coincident with infection, but addition of drug at 8 hpi
reduced yield by 45-fold, indicating that a substantial portion of
ouabain's antiviral effect occurs prior to 8 h post-infection.
Ouabain does not meaningfully inhibit attachment or entry
In order to investigate the stage of the viral replication cycle
inhibited by ouabain, we performed attachment and entry
assays. Using a standard assay for attachment (MacLean, 1998,
Shogan et al., 2006), Vero cells and HSV were pre-chilled toTable 1
Antiviral effect compared to inhibition of the sodium potassium ATPase
Compound Drug concentration that reduces
Na/K ATPase activity by 50%
Drug concentration that
reduces viral yield by 90%
Ouabain 23 nM 40 nM
Bufalin 53 nM 15 nM
Digitoxin 78 nM 70 nM
Digoxin 120 nM 150 nM
Strophanthidin 180 nM 500 nM
Ouabagenin 640 nM 2500 nM
Vero cells were infected with wild-type HSVat an MOI of 10, and treated with a
range of concentrations of the indicated inhibitors of the sodium potassium
pump. Viral yield was determined by titration at 24 h post-infection. The right
column contains the concentration of each drug that was sufficient to reduce
viral yield by 90%. The middle column contains previously reported
concentrations of drug that inhibited ATPase activity of cardiac membrane
extracts by 50% (Pullen et al., 2004).4 °C. The chilled cells were infected with approximately
150 PFU of HSV in the presence of ouabain on ice for 1 h to
permit attachment. Unbound virus and drug were washed off
and infection was allowed to proceed for 48 h. This assay was
performed four times, testing concentrations including 10 nM (a
concentration that did not reduce viral yield), 100 nM, 1 μM and
10 μM. No effect on plaque formation was observed at any of
these concentrations. In a representative experiment, untreated
cells produced 152 plaques while cells treated with 100 nM
ouabain, a concentration that reduces viral yield by 100- to
10,000-fold, produced 146 plaques. To assess effects on
attachment at higher MOI, cells were infected with virus at an
MOI of 10 on ice for 1 h in the presence or absence of 100 nM
ouabain. This permitted viral attachment to cells without viral
entry. Cells were then washed to remove the drug and any un-
attached virions. Fresh, drug-free media were then added, and
infection was allowed to proceed at 37 °C for 24 h. Yields from
the treated culture (1.3×108 PFU/ml) were similar to those from
untreated cultures (1.2×108 PFU/ml). Thus, in both the stan-
dard attachment assay and the high MOI attachment assay,
treatment with ouabain had little or no effect.
To determine if pre-attached virus was able to enter cells in
the presence of drug, a standard entry assay was performed
(MacLean, 1998, Shogan et al., 2006). Chilled, untreated cells
were infected with approximately 300 PFU of chilled virus and
left on ice for 1 h to permit attachment. Unbound virus was
washed off and entry was allowed to proceed at 37 °C for 1 h inFig. 6. Effect of delayed ouabain addition on viral yield. Cells were infected with
wild-type HSV-1 at an MOI of 10 and treated with 100 nM ouabain at the
indicated times post-infection. Viral yield was determined by titration at 24 h
post-infection.
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that reduces viral yield by 100- to 10,000-fold. Drug was
washed out, and cells were treated with acidic buffer to
neutralize any remaining extracellular virus. Infection was then
allowed to continue at 37 °C in drug-free media for 48 h. In this
assay, the untreated cells produced 272 plaques while the treated
cells produced 245 plaques. Thus, treatment with ouabain did
not substantially reduce the number of viral plaques in this entry
assay. To assess effects on entry at higher MOI, we allowed
HSV-1 to attach to cells on ice for 1 h at an MOI of 10 in the
absence of drug. Infected cells were then moved to 37 °C for 1 h
in the presence or absence of 100 nM ouabain, a concentration
which reduces viral yield by 100- to 10,000-fold (as verified in a
parallel assay). At the end of 1 h, all cells were treated with an
acidic buffer to inactivate remaining extracellular virus.
Infection then proceeded in drug-free media for 24 h. Untreated
cells produced a yield of 9.0×106 PFU/ml and treated cells
produced a yield of 9.6×106 PFU/ml. Thus, in both the standard
entry assay and the high MOI entry assay, pre-attached virus
was able to enter cells in the presence of drug.
Ouabain inhibits expression of immediate–early and early
genes
The screening assay showed that expression of the ICP8-
GFP early gene marker was reduced by 5-fold, which was the
limit of detection, in the presence of ouabain. To confirm and
extend this finding, we assessed expression of the viral
immediate–early protein ICP27 by Western blot analysis.
Vero cells were infected with wt HSV-1 at an MOI of 10 in
the presence or absence of 100 nM ouabain. At 6 h post-
infection, cells were lysed and processed for SDS–PAGE and
Western Blotting using H1113, a monoclonal antibody against
ICP27 (Fig. 7). A specific band for ICP27 was visible in the
infected cell lysate (lanes 1–4) and absent in uninfected cell
lysate (lane 5), and lysates from ouabain-treated infected cellsFig. 7. Effect of ouabain on ICP27 expression. Cells were infected or mock
infected in the presence or absence of ouabain. Protein lysates were harvested at
6 h post-infection, and ICP27 was detected by western blot using a monoclonal
antibody against ICP27 (top panel). Wells 1–4 contain a series of two-fold
dilutions of infected, untreated cell lysate into loading buffer (lane 1 contains
undiluted sample, and lane 4 contains a 1:8 dilution). Lane 5 contains undiluted
lysate from mock-infected cells and lane 6 contains undiluted lysate from
infected, ouabain-treated cells. The blot was stripped and reprobed using a
monoclonal antibody against β-actin (bottom panel).(lane 6). Comparison of the lysate from ouabain-treated infected
cells with a dilution series of infected cell lysate (lanes 2–4)
permitted an estimate that the reduction was at least 8-fold. The
blot was stripped and probed with anti-actin antibody, which
showed that the lysates contained similar amounts of protein
(Fig. 7, bottom panel, lanes 1, 5 and 6). Thus, ouabain acts at or
prior to the expression of immediate–early proteins.
Discussion
We set out to test an approach for chemical screening
targeted at a specific stage in the HSV replication cycle. The
approach identified a novel inhibitor of HSV replication that
acts at an early step in viral replication soon after entry and
before immediate–early gene expression. The identification of
ouabain as an inhibitor is intriguing as there were few previous
results that suggested a role for a Na/K pump in HSV
replication.
Temporally controlled reporters are a viable method for
identifying stage-specific anti-viral inhibitors
Our screening approach took advantage of the temporal
regulation of HSV replication to isolate compounds with
specificity for stages prior to the expression of viral early
genes. This cell-based approach also assured that the com-
pounds would be relevant to viral infection. This is not the first
such cell-based infection assay for inhibitors of HSV replica-
tion. One group, Van Zeijl et al. (2000), conducted a screen
using an automated ELISA assay to determine viral yield, and
another group, Boulware et al. (2001), placed the lacZ reporter
under the control of the promoter for the viral glycoprotein C,
which is expressed late in infection. However, to our knowl-
edge, our screen is the first attempt to specifically exclude
inhibitors of viral DNA replication and later steps. The
identification of ouabain from our screen is proof in principle
that our screening approach has the potential to identify novel
compounds that inhibit specific stages in the replication of HSV.
The screening approach was not without limitations. The
initial screen had an undesirably high hit rate, primarily because
the readout was the loss of expression of a protein. Cytotoxic
compounds, and those which are general inhibitors of
translation, will prevent expression of the GFP marker used in
this assay without shedding any useful insight on mechanisms
of viral infection. For this reason, we were greatly concerned
about cytotoxicity as a source of true, but uninteresting, positive
hits. A larger scale screen using this assay would have to cope
with this issue, either by improved sensitivity or additional
secondary assays to confirm hits and remove cytotoxic
compounds. However, even without adjustments to the assay
conditions, advances in screening equipment such as micro-
scopes with higher resolution and sensitivity might help
decrease the number of false or uninteresting positives detected
by the screen. This might also help lower the initial hit rate and
thus facilitate the secondary screening process.
Despite these limitations, we were able to implicate a cellular
component that had not been strongly considered for a role in
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sodium potassium pump would be involved in steps of infection
prior to early gene expression, so it is unlikely that it would have
been selected as a hypothetical candidate for investigation in an
in vitro screening assay. Screening in live cells with whole virus
ultimately allows the greatest diversity of potential hits, and the
results of our study have validated this approach.
Ouabain inhibits a pre-gene expression step in HSV infection
Ouabain reduced HSV replication in Vero cells by over 100-
fold in yield reduction assays. Data from the attachment and
entry assays, as well as the result that drug can be removed at up
to 8 h post-infection without reducing viral yield, argue strongly
that ouabain acts at a stage after fusion with the plasma
membrane. Data from the ICP8-GFP assay and the Western blot
analysis show reduction of expression of viral immediate–early
and early genes by at least 5-fold. Neither cellular nuclear
morphology, as observed via Hoechst staining, nor cellular
metabolic activity, as measured by the WSTcleavage assay, was
affected by ouabain treatment for the length of time used in
these assays. In addition, the effects of ouabain were reversible
when drug was removed up to 8 h post-infection, or after an
overnight pre-treatment. Collectively, these data suggest that
ouabain is inhibiting one of the stages of the viral life cycle that
the screen was intended to target, and that its effect is not
primarily due to gross cytotoxicity. We also observed a decrease
in viral yield in the single cycle growth assay even if drug was
added at 8 h post-infection, after viral DNA replication should
have occurred. This additional effect may be due to cytotoxicity,
or due to a specific effect on a later stage of herpes viral
replication. One possible late stage target is egress, as ouabain
has been reported to inhibit fusion of cells infected with
syncytial mutant strains of HSV-1 (Baghian and Kousoulas,
1993). We endeavored to limit the time of ouabain exposure in
subsequent experiments to better separate effects on the early
stages of viral replication from any later effects.
Ouabain has been previously stated to have an anti-viral
effect (Baghian and Kousoulas, 1993), but to our knowledge
data to support this conclusion and examine its mechanism have
not been reported. The results of our experiments suggest that
ouabain is targeting either transport of the viral capsid to the
nucleus, uncoating of the capsid to allow translocation of the
viral genome, processes that allow viral proteins such as VP16
through the nuclear pore, or more directly, expression of viral
genes. Interestingly, it has been reported that depolymerization
of the microtubule network with nocodazole, which disrupts
transport of the capsid to the nucleus, reduces expression of a
reporter expressed with early kinetics by 80–90% (Mabit et al.,
2002).
Empirical observations aside, the molecular mechanism of
ouabain's antiviral effects is not entirely clear. We were not able
to generate resistant viral mutants to ouabain (not shown). This is
consistent with the hypothesis that the antiviral effect is due to
inhibition of a cellular target, but could also be explained by
inhibition of both a cellular and a viral target, or inhibition of
both an early viral target and also a later stage such as egress,either of which would make it more difficult to develop
resistance. The experiments with other cardiac glycosides,
which indicated that antiviral potency for all but bufalin
correlated with potency for ouabain's known cellular receptor,
support the argument that the antiviral effect is due to the
compounds' inhibition of the sodium potassium pump. Bufalin,
while structurally similar to the plant-derived cardiac glycosides,
is derived from toad venom and has been reported to poison
topoisomerase II (Pastor and Cortes, 2003). Host topoisomerase
II has been shown to act on progeny HSV genomes (Ebert et al.,
1994) and an inhibitor of topoisomerase II has been reported to
reduce viral yield by greater than 50% (Hammarsten et al.,
1996), so this activity could explain the higher than expected
potency of bufalin against viral yield compared to ouabain. The
sodium potassium pump is also necessary for proper cellular
calcium homeostasis and is active in cellular signaling pathways
(reviewed in Xie and Cai, 2003), presenting a wide array of
pathways that could explain its antiviral effect. Studies to
determine how inhibition of an ion pump leads to an effect on a
specific stage of HSV infection are ongoing.
Materials and methods
Cells and viruses
Vero (African green monkey kidney) cells were obtained
from the American Type Culture Collection and grown and
maintained in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 5% newborn calf serum (2% during infection
where not otherwise noted) and 1% penicillin–streptomycin
(Invitrogen) at 37 °C and 5% CO2. HSV type 1 (HSV-1) wild-
type strain KOS was propagated in Vero cells. The ICP8-GFP
virus was derived from KOS 1.1 as previously described (Taylor
et al., 2003). ICP8-GFPwas grown in V529 cells, a Vero line that
contains the UL5 and UL29 genes, in order to complement the
partial replication defect of the ICP8-GFP virus.
Chemicals
The ICCB known bioactive compound library consists of
480 small molecules with previously observed biologic activity.
The entire library as a set is commercially available from
Biomol and is fully annotated online at the ICCB Web site
(http://iccb.med.harvard.edu/screening/compound_libraries/
bioactives_collection2.htm). The pilot screen used stocks stored
in DMSO at concentrations of 5 mg/ml (on average,
approximately 10 mM) at −20 °C in desiccated storage
containers. Ouabain (Biomol) and other inhibitors of the
sodium potassium pump (VWR) were suspended at 10 mM in
DMSO and stored at 4 °C. Hoechst 33258 (Sigma) was
suspended in water at a concentration of 10 mg/ml.
Screening assay
The assay was conducted in duplicate using black walled,
clear-bottomed 384-well cell culture plates (Corning) filled
using a Matrix Wellmate plate filler. Vero cells were seeded at a
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incubated overnight at 37 °C. To reduce background, phenol
red-free, glutamine-free DMEM (Cellgro) supplemented with
2 mM glutamine, 2% NCS and 1% penicillin–streptomycin was
used. Plates were fully confluent at the time of compound
addition to maximize the number of infectable cells in each
well. Compounds from the library were added to the media
(estimated working concentration 30 μM) by a custom pin-
transfer robot built for the ICCB. The Vero cells were then
infected with ICP8-GFP virus at an MOI of 20, which was
experimentally determined to be sufficient to detect GFP signal
in 70–80% of the cells at 18 h post-infection. (The MOI of this
infection was determined on the complementing V529 cells.
Although the virus is impaired for DNA replication in wild-type
Vero cells, it was deemed appropriate to use titers from the
complementing cell line because the readout of the assay occurs
prior to the block.) At 18 h post-infection, cells were fixed and
stained for 30 min by addition of 8% paraformaldehyde in PBS,
including 1:5000 of a 10 mg/ml Hoechst 33258 stock solution
added just prior to treatment, directly to the infected cells in
drug-containing media. The plates were aspirated with a 24-
channel aspirating wand (VP Scientific) and washed twice with
PBS. Plates were filled with PBS, sealed with foil seals
(Corning) and stored at 4 °C prior to screening.
A Discovery-1 high content screening microscope (Uni-
versal Imaging) was programmed to visualize fluorescent
signal from the Hoechst stain, automatically focus on cell
nuclei and record an image. The cells were then illuminated at
488 nm to produce signal from GFP, and a second image was
taken in the same focal plane as the nuclei. Metamorph image
analysis software (Molecular Devices) was then used to
quantify the signal. This software identifies the nuclei as
objects, measures the corresponding areas of the GFP channel
images and calculates a total amount of signal recorded from
the objects in each of the two channels. The mean and standard
deviation for all samples, including both duplicates, were
determined. The individual wells were then compared to these
aggregate numbers to identify potential hits and cytotoxic
compounds. A compound was scored as a potential hit if both
of the two duplicates had GFP signal reduced by one standard
deviation or more below the mean for all compounds screened.
Visual inspection of the plates revealed that compounds that
reduced the amount of Hoechst signal detected by one standard
deviation or more in either of the two duplicates were causing
visible changes in nuclear structure or number. Therefore, this
standard was adopted for rejection of potential hits due to
cytotoxicity.
Yield reduction assay
All yield reduction assays were conducted on Vero cells
using wild-type strain KOS at an MOI of 10 in cell culture
tubes, in DMEM containing 2% serum and 1% penicillin–
streptomycin. Where not otherwise noted, drugs were added
simultaneously with virus and media was not changed. Virus
was harvested at 24 h post-infection by freeze thawing the entire
culture tube three times, followed by titration on Vero cells.WST cytotoxicity assay
WST-1 was obtained from Roche and was used according to
the manufacturer's instructions. Cells were plated on black 96-
well plates to replicate the conditions used in the screening and
yield assays. Cells were treated with a range of concentrations of
ouabain for 24 h.WST-1was added to each well for 30min at the
recommended 1:10 dilution and the plate was left in a 37 °C
incubator with CO2 for 1 h to allow for reduction by cells. This
reaction produced colored product proportional to the number of
metabolically active cells in the well. A standard curve was
generated by plating 2-fold dilutions of a 6×106 cells/ml
solution immediately prior to the assay, which had a linear range
of approximately 1500 to 200,000 cells per well. The absorbance
produced by the experimental samples corresponded to a
number of cells (approximately 80,000 cells/well) that lay
within the linear range of the standard curve. Absorbance at
440 nm was quantified in a Wallac 1420 plate reader.
Attachment assay
The effects of compounds on attachment were assessed using
a previously described assay (modified in Shogan et al., 2006,
from a standard protocol in MacLean, 1998). In this assay
(standard assay of attachment), Vero cell monolayers were pre-
chilled to 4 degrees and infected with approximately 150–
300 PFU of wild-type HSV-1 strain KOS in the presence or
absence of compounds for 1 h on ice. We also performed a high
MOI assay of attachment, in which Vero cells in cell culture
tubes were infected at anMOI of 10 in the presence or absence of
compounds on ice for 1 h. This incubation is long enough to
permit the majority of the inoculum to attach to cells (B. Shogan,
A.W.D., and D.M.C., unpublished results). In both assays, cells
were washed with PBS three times, to remove compounds and
unattached virus, and overlaid with drug-free medium containing
1.2% methylcellulose in the standard assay, or unsupplemented
drug-free medium in the high MOI assay. For the standard assay,
infection was allowed to proceed at 37° for 48 h, after which
cells were fixed and stained for plaque counting. Virus from the
high MOI assay was harvested at 24 h post-infection by freeze
thawing the entire culture tube three times, followed by titration
on Vero cells. As a control to show that entry does not occur
during the attachment step in this assay, cells with attached virus
were treated with acidic glycine as described for the entry assay
below, and no plaques were observed. Known inhibitors of viral
attachment such as heparin inhibit plaque formation in this assay
(L. Kruse, B. Shogan, E. Macari, A.W.D., and D.M.C., unpub-
lished results and Shogan et al., 2006).
Entry assay
The effects of compounds on entry were assessed using a
previously described assay (modified in Shogan et al., 2006,
from a standard protocol in MacLean, 1998). In this assay
(standard assay of entry), Vero cell monolayers were pre-chilled
to 4 degrees, and infected with approximately 150–300 PFU of
wild-type HSV-1 strain KOS in drug-free medium for 1 h on ice
347A.W. Dodson et al. / Virology 366 (2007) 340–348in minimal volume to permit attachment. We also performed a
high MOI assay of entry, in which Vero cells in cell culture
tubes were infected at an MOI of 10 on ice for 1 h. In both
assays, cells were washed three times with chilled PBS to
remove unattached virus and overlaid with medium containing
compounds. Entry was allowed to proceed at 37° for 1 h, an
incubation which is long enough to permit the majority of pre-
attached virus to enter cells (L. Kruse, B. Shogan, E. Macari, A.
W.D., and D.M.C., unpublished results), and then 1 ml of acidic
glycine was added to cells to inactivate remaining extracellular
virus. After 20 s of treatment at room temperature, cells were
washed three times with medium to return the pH to neutral. For
the standard assay, cells were then overlaid with medium
containing 1.2% methylcellulose, incubated at 37 °C for 2 days
and fixed and stained to count plaques. We have previously
shown that a phosphorothioate oligonucleotide inhibits entry in
this assay (Shogan et al., 2006). Virus from the high MOI assay
was harvested at 24 h post-infection by freeze thawing the entire
culture tube three times, followed by titration on Vero cells.
Western blot analysis
Confluent 60-mm dishes of Vero cells were mock infected or
infected with wild-type HSV-1 strain KOS for 6 h in the
presence or absence of 100 nM ouabain, added simultaneously
with virus. After 6 h, cells were washed three times with 3 ml of
PBS for 30 s at room temperature. Protein lysates were
harvested by addition of 350 μl of 2× Laemmli sample buffer
(Bio-Rad) supplemented with 0.7 M β-mercaptoethanol (Bio-
Rad). Lysates were boiled for 5 min, frozen and boiled again
immediately prior to loading on 10% SDS–polyacrylamide
gels. Infected cell lysate samples with and without ouabain were
diluted in Laemmli buffer to generate standard curves for
quantifying amounts of protein present.
For immunodetection of the ICP27 protein, membranes were
blocked overnight in TBST (20 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 1% Tween 20) supplemented with 5% milk. H1113
mouse monoclonal antibody (Virusys) against ICP27 was added
to the blocking solution at 1:5000 for 1 h at room temperature.
Blots were washed three times for 5 min each in TBST and goat
anti-mouse HRP-conjugated secondary antibody (Southern
Biotech) was added in 1:5000 TBST. Blots were washed
again three times for 5 min each in TBST and enhanced
chemiluminescence reagents were used as directed by the
manufacturer (Pierce). Blots were stripped using Restore
Western Stripping Buffer (Bio-Rad) for 1 h at room tempera-
ture, followed by re-blocking overnight and reprobing as
described above with 1:5000 anti-actin monoclonal antibody
(Abcam) in blocking solution as a loading control.
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Note added in proof
After this paper appeared online, we were made aware of a
recent paper (Hartley, C., Hartley, M., Pardoe, I., Knight, A.,
2006. Ionic contra-viral therapy (ICVT): a new approach to
the treatment of DNA virus infections. Arch. Virol. 151,
2495–2501) that reported inhibition of HSV plaque formation
by the cardiac glycoside digoxin.
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